RT @purviparwani: Great article on @jaccjournals on effect of PCSK9i on Lp(a) ➡PCSK9i caused 23% reduction in Lp(a) ⬇️in Lp(a) related to…
@renecardio4 @sigal_alan @LipidosSal @lynchsantiago @ferbotto @CardioBornan @lschreier1 @DanielPiskorz @alavallecobo @drdiegocosta @EmmanuelScatu Este es el de Odyssey tb sobre Lp(a) https://t.co/018lu1xaTo
🎉 Vera Bittner, MD, MSPH, has been included in the @ACCinTouch Top Picks for 2020 for her recent study on the effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome. https://t.co/xPencpVwgz @UABCardiology https://t.co
13/20 7-In FOURIER and Odyssey Outcomes, the highest quartile of Lp(a) was associated with highest risk in both studies 8-Alirocumab in OO reduced Lp(a)-mediated risk, accounting for nearly 1/3rd of the benefit noted in that study https://t.co/n0eRRQloBG